Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.

Find People
Find Everything
About This Site
Edit My Profile
Export RDF
Login to Profiles

Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.

März W, Dippel FW, Theobald K, Gorcyca K, Iorga SR, Ansell D. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis. 2018 01; 268:99-107.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Cardiovascular Diseases
Cholesterol, LDL
Comorbidity
Cross-Sectional Studies
Databases, Factual
Down-Regulation
Dyslipidemias
Evidence-Based Medicine
Female
Germany
Guideline Adherence
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Middle Aged
Practice Guidelines as Topic
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome

authors with profiles

David Ansell